Skip Ribbon Commands
Skip to main content

PAMED Policy on Medical Marijuana

Here is the Pennsylvania Medical Society's official position on medical marijuana as stated in 95.995 of PAMED's Policy Compendium:

95.995 Use of Medical Marijuana

The Society adopted AMA policy H-95.952 as the policy of the Pennsylvania Medical Society with respect to the use of cannabis for medical purposes:

  1. calls for further adequate and well-controlled studies of marijuana and related cannabinoids in patients who have serious conditions for which preclinical, anecdotal, or controlled evidence suggests possible efficacy and the application of such results to the understanding and treatment of disease;
  2. urges that marijuana's status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines, and alternate delivery methods. This should not be viewed as an endorsement of state-based medical cannabis programs, the legalization of marijuana, or that scientific evidence on the therapeutic use of cannabis meets the current standards for a prescription drug product;
  3. urges the National Institutes of Health (NIH) to implement administrative procedures to facilitate grant applications and the conduct of well-designed clinical research into the medical utility of marijuana. This effort should include: a) disseminating specific information for researchers on the development of safeguards for marijuana clinical research protocols and the development of model informed consent on marijuana for institutional review board evaluation; b) sufficient funding to support such clinical research and access for qualified investigators to adequate supplies of marijuana for clinical research purposes; c) confirming that marijuana of various and consistent strengths and/or placebo will be supplied by the National Institute on Drug Abuse to investigators registered with the Drug Enforcement Agency who are conducting bona fide clinical research studies that receive Food and Drug Administration approval, regardless of whether or not the NIH is the primary source of grant support; and
  4. believes that effective patient care requires the free and unfettered exchange of information on treatment alternatives and the discussion of these alternatives between physicians and patients should not subject either party to criminal sanctions.  (Board of Trustees, February 2-3, 2010)

Medical Use of Cannabinoids
The Society opposes broad-based legalization of cannabis for medical use and adopted the following principles:

  1. The Pennsylvania Medical Society calls for further adequate and well-controlled studies of marijuana and related cannabinoids in patients who have serious conditions for which preclinical, anecdotal, or controlled evidence suggests possible efficacy and the application of such results to the understanding and treatment of disease.
  2. The Pennsylvania Medical Society urges that marijuana's status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines, and alternate delivery methods. This should not be viewed as an endorsement of state-based medical cannabis programs, the legalization of marijuana, or that scientific evidence on the therapeutic use of cannabis meets the current standards for a prescription drug product.
  3. The Pennsylvania Medical Society urges the National Institutes of Health (NIH) to implement administrative procedures to facilitate grant applications and the conduct of well-designed clinical research into the medical utility of marijuana. This effort should include: a) disseminating specific information for researchers on the development of safeguards for marijuana clinical research protocols and the development of model informed consent on marijuana for institutional review board evaluation; b) sufficient funding to support such clinical research and access for qualified investigators to adequate supplies of marijuana for clinical research purposes; c) confirming that marijuana of various and consistent strengths and/or placebo will be supplied by the National Institute on Drug Abuse to investigators registered with the Drug Enforcement Agency who are conducting bona fide clinical research studies that receive Food and Drug Administration approval, regardless of whether or not the NIH is the primary source of grant support.
  4. The Pennsylvania Medical Society believes that effective patient care requires the free and unfettered exchange of information on treatment alternatives and the discussion of these alternatives between physicians and patients should not subject either party to criminal sanctions.
  5. The Pennsylvania Medical Society supports trials using cannabidiol oil to treat children with seizure disorders, funding for the trials, and a patient registry.  (Res. 403, H-2015)

Please Log in to comment/rate on this article.

Article Rating

Total Rating:

Loading...

Your Rating:

Loading...
Click stars to adjust rating

Submit Rating

You must be logged in to comment on this article

Related Content

Article of

Pennsylvania Medical Society Statement on the Pennsylvania Medical Marijuana Act

Learn More